Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 125Myelodysplastic Syndromes 120Precursor Cell Lymphoblastic Leukemia-Lymphoma 107Leukemia 86Hodgkin Disease 81Leukemia, Lymphocytic, Chronic, B-Cell 78Lymphoma 76Multiple Myeloma 75Lymphoma, Non-Hodgkin 75Myeloproliferative Disorders 57Graft vs Host Disease 55Lymphoma, Follicular 54Lymphoma, Mantle-Cell 50Lymphoma, Large B-Cell, Diffuse 50Leukemia, Myeloid, Accelerated Phase 50Leukemia, Myelomonocytic, Chronic 48Congenital Abnormalities 48Leukemia, Myelogenous, Chronic, BCR-ABL Positive 47Hematologic Neoplasms 45Lymphoma, B-Cell, Marginal Zone 44Leukemia, Myeloid, Chronic-Phase 44Burkitt Lymphoma 42Primary Myelofibrosis 41Blast Crisis 39Neoplasms, Plasma Cell 38Lymphoma, Large-Cell, Immunoblastic 34Waldenstrom Macroglobulinemia 26Myelodysplastic-Myeloproliferative Diseases 25Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 25Anemia, Refractory, with Excess of Blasts 24

Interventions

Cyclophosphamide 3thymoglobulin 2luspatercept 2fludarabine 2Rituximab 2Melphalan 2Busulfan 2fludarabine phosphate 1Whole-Body Irradiation 1Thiotepa 1Tacrolimus 1Sugammadex 1Mycophenolic Acid 1Levetiracetam 1Dexamethasone 1Bortezomib 1Antilymphocyte Serum 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
beta-Thalassemia × Tacrolimus × Clear all
NCT05736419 2026-06-03

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
24 enrolled
Classical hematology

Anemia, Sickle Cell, Thalassemia, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡